16.10
15.83%
+2.20
アフターアワーズ:
16.16
0.06
+0.37%
Stoke Therapeutics Inc (STOK) 最新ニュース
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Business Wire
Investors in Stoke Therapeutics (NASDAQ:STOK) have unfortunately lost 64% over the last three years - Yahoo Movies Canada
Yahoo Movies Canada
Taking the lead: Stoke Therapeutics Inc (STOK) – Sete News - SETE News
SETE News
Stoke Therapeutics (STOK) Price Target Decreased by 13.91% to 22.44 - MSN
MSN
Selling Buzz: Stoke Therapeutics Inc [STOK] CHIEF MEDICAL OFFICER Ticho Barry sells 10000 shares of the ... - Knox Daily
Knox Daily
When the Price of (STOK) Talks, People Listen - Stock Traders Daily
Stock Traders Daily
Stoke Therapeutics (NASDAQ:STOK) Trading Up 6.4% - MarketBeat
MarketBeat
STOK overperforms with a 10.82 increase in share price – US Post News - US Post News
US Post News
Stoke Therapeutics Inc (STOK) Becoming More Attractive for Investors – Knox Daily - Knox Daily
Knox Daily
Los Angeles Capital Management LLC Grows Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Defense World
Stoke Therapeutics (NASDAQ:STOK) Shares Down 6.4% - Defense World
Defense World
Stoke Therapeutics, Inc. (NASDAQ:STOK) Sees Significant Growth in Short Interest - MarketBeat
MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Forecasted to Post FY2024 Earnings of ($2.51) Per Share - Defense World
Defense World
Stoke Therapeutics (NASDAQ:STOK) Trading Down 6.4% - MarketBeat
MarketBeat
Stoke Therapeutics, Inc. Expected to Post FY2024 Earnings of ($2.51) Per Share (NASDAQ:STOK) - MarketBeat
MarketBeat
Research Analysts Issue Forecasts for Stoke Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:STOK) - Defense World
Defense World
Stoke Therapeutics (NASDAQ:STOK) Trading Down 6.4% - MarketBeat
MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Expected to Post FY2028 Earnings of $0.17 Per Share - MarketBeat
MarketBeat
Stoke Therapeutics Inc [STOK] Records 200-Day SMA of $6.19 – Knox Daily - Knox Daily
Knox Daily
Q2 2024 EPS Estimates for Stoke Therapeutics, Inc. (NASDAQ:STOK) Lowered by Wedbush - Defense World
Defense World
Stoke Therapeutics (NASDAQ:STOK) Given “Buy” Rating at HC Wainwright - Defense World
Defense World
Stoke Therapeutics (NASDAQ:STOK) Price Target Lowered to $20.00 at Canaccord Genuity Group - Defense World
Defense World
Stoke Therapeutics (NASDAQ:STOK) Rating Reiterated by Needham & Company LLC - Defense World
Defense World
The growth track for Stoke Therapeutics Inc (STOK) has changed recently – Sete News - SETE News
SETE News
Canaccord Genuity Group Trims Stoke Therapeutics (NASDAQ:STOK) Target Price to $20.00 - MarketBeat
MarketBeat
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates - citybiz
citybiz
Analyst Expectations For Stoke Therapeutics's Future
Benzinga
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Yahoo Finance
Stoke Therapeutics : Corporate Presentation - May 2024 - Marketscreener.com
Marketscreener.com
Stoke Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 - Marketscreener.com
Marketscreener.com
Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC - MarketBeat
MarketBeat
Stoke therapeutics CMO sells $113,653 in stock By Investing.com - Investing.com
Investing.com
Stoke therapeutics CMO sells $113,653 in stock By Investing.com - Investing.com
Investing.com
It makes sense and dollars to buy Stoke Therapeutics Inc (STOK) stock – Sete News - SETE News
SETE News
Stoke Therapeutics Inc [STOK] Investment Appeal on the Rise – Knox Daily - Knox Daily
Knox Daily
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Zacks Investment Research
Investor's Toolkit: Key Ratios for Assessing Stoke Therapeutics Inc (STOK)'s Performance – DWinneX - The Dwinnex
The Dwinnex
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer - citybiz
citybiz
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer - Business Wire
Business Wire
Stoke Therapeutics Chief Financial Officer Stephen Tulipano Resigns - MarketWatch
MarketWatch
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Zacks Investment Research
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline - Yahoo Finance
Yahoo Finance
Skorpios Trust sells $41.76 million of Stoke Therapeutics stock - Investing.com Canada
Investing.com Canada
Stoke Therapeutics, Inc. (NASDAQ:STOK) Major Shareholder Sells $41,760,000.00 in Stock - MarketBeat
MarketBeat
Stoke Therapeutics appoints new CCO for drug launch By Investing.com - Investing.com Nigeria
Investing.com Nigeria
Stoke Therapeutics' $125 Million Upsized Common Stock Offering – Global Legal Chronicle - Global Legal Chronicle
Global Legal Chronicle
Assessing Stoke Therapeutics: Insights From 6 Financial Analysts
Benzinga
Stoke Therapeutics Stock: Dravet Data Sends Shares Soaring One For Watchlist (NASDAQ:STOK) - Seeking Alpha
Seeking Alpha
Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
Seeking Alpha
Stoke Therapeutics Launches Public Offering for Clinical Development - TipRanks.com - TipRanks
TipRanks
大文字化:
|
ボリューム (24 時間):